Low-Dose TKIs Before Treatment Discontinuation Do Not Impair Treatment-Free Remission in CML Patients
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Low-Dose Tyrosine Kinase Inhibitors Before Treatment Discontinuation Do Not Impair Treatment-Free Remission in Chronic Myeloid Leukemia Patients: Results of a Retrospective Study
Cancer 2020 May 27;[EPub Ahead of Print], E Cayssials, J Torregrosa-Diaz, P Gallego-Hernanz, F Tartarin, T Systchenko, N Maillard, D Desmier, A Machet, E Fleck, A Corby, C Motard, G Denis, A Herbelin, JM Gombert, L Roy, S Ragot, X Leleu, F Guilhot, JC ChomelFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.